<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179359</url>
  </required_header>
  <id_info>
    <org_study_id>2014OC034</org_study_id>
    <secondary_id>MT2014-10C</secondary_id>
    <nct_id>NCT02179359</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies</brief_title>
  <official_title>MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to collect the outcomes of stem cell transplantation for patients with
      hematologic diseases other than cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2014</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of graft failure</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>6 months, 1 and 2 years</time_frame>
    <description>patient no longer needing red blood cell transfusion and/or a hemoglobin S level at that of the donor ( sickle cell disease only)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Transfusion Dependent Alpha- or Beta- Thalassemia</condition>
  <condition>Diamond Blackfan Anemia</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Glanzmann Thrombasthenia</condition>
  <condition>Severe Congenital Neutropenia</condition>
  <condition>Shwachman-Diamond Syndrome</condition>
  <condition>Non-Malignant Hematologic Disorders</condition>
  <arm_group>
    <arm_group_label>Reduced Toxicity Ablative Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are &lt;12 years and/or have mild/moderate iron exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced Intensity Preparative Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For use in patients with unrelated donor bone marrow and for DBA patients who are &gt;12 years and/or have significant iron exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloablative Preparative Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Toxicity Ablative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Stem Cell Infusion Day 0</description>
    <arm_group_label>Reduced Toxicity Ablative Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced Intensity Preparative Regimen</intervention_name>
    <description>Alemtuzumab
Cyclophosphamide
Fludarabine
Total Body Irradiation (TBI)
Stem Cell Infusion Day 0</description>
    <arm_group_label>Reduced Intensity Preparative Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myeloablative Preparative Regimen</intervention_name>
    <description>Alemtuzumab
Cyclophosphamide
Busulfan
Stem Cell Infusion Day 0</description>
    <arm_group_label>Myeloablative Preparative Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other
             non-malignant hematologic disorders for which a stem cell transplant is indicated

          -  Acceptable stem cell source identified

          -  Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score)

          -  Creatinine &lt;2.0 mg/dl for adults or glomerular filtration rate &gt; 50 ml/min for
             children

          -  Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase &lt;5 times the upper limit
             of institutional normal

          -  Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left
             ventricular ejection fraction &gt; 40%

        Exclusion Criteria:

          -  active, uncontrolled infection

          -  pregnant or breastfeeding

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Thrombasthenia</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Lipomatosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

